TNXP vs. INAB, CUE, NAII, LPCN, LIAN, ICCC, PLUR, VYNE, NKGN, and RVPH
Should you be buying Tonix Pharmaceuticals stock or one of its competitors? The main competitors of Tonix Pharmaceuticals include IN8bio (INAB), Cue Biopharma (CUE), Natural Alternatives International (NAII), Lipocine (LPCN), LianBio (LIAN), ImmuCell (ICCC), Pluri (PLUR), VYNE Therapeutics (VYNE), NKGen Biotech (NKGN), and Reviva Pharmaceuticals (RVPH). These companies are all part of the "pharmaceutical products" industry.
Tonix Pharmaceuticals (NASDAQ:TNXP) and IN8bio (NASDAQ:INAB) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, community ranking, dividends and institutional ownership.
Tonix Pharmaceuticals' return on equity of -83.03% beat IN8bio's return on equity.
Tonix Pharmaceuticals has a beta of 2.12, meaning that its stock price is 112% more volatile than the S&P 500. Comparatively, IN8bio has a beta of 0.06, meaning that its stock price is 94% less volatile than the S&P 500.
IN8bio has lower revenue, but higher earnings than Tonix Pharmaceuticals. IN8bio is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Tonix Pharmaceuticals received 318 more outperform votes than IN8bio when rated by MarketBeat users. However, 70.97% of users gave IN8bio an outperform vote while only 63.43% of users gave Tonix Pharmaceuticals an outperform vote.
Tonix Pharmaceuticals presently has a consensus price target of $53.50, indicating a potential upside of 9,627.27%. IN8bio has a consensus price target of $10.00, indicating a potential upside of 1,091.90%. Given Tonix Pharmaceuticals' higher probable upside, equities analysts plainly believe Tonix Pharmaceuticals is more favorable than IN8bio.
In the previous week, Tonix Pharmaceuticals had 6 more articles in the media than IN8bio. MarketBeat recorded 8 mentions for Tonix Pharmaceuticals and 2 mentions for IN8bio. IN8bio's average media sentiment score of 1.44 beat Tonix Pharmaceuticals' score of 0.66 indicating that IN8bio is being referred to more favorably in the news media.
82.3% of Tonix Pharmaceuticals shares are held by institutional investors. Comparatively, 92.1% of IN8bio shares are held by institutional investors. 0.5% of Tonix Pharmaceuticals shares are held by company insiders. Comparatively, 15.5% of IN8bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
Tonix Pharmaceuticals beats IN8bio on 8 of the 14 factors compared between the two stocks.
Get Tonix Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for TNXP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TNXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tonix Pharmaceuticals Competitors List
Related Companies and Tools
